MAP
IDXG

Managed Asset Portfolios’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Managed Asset Portfolios’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-100
Closed -$24K – 43
2014
Q3 		$24K Hold
100
– – 0.01% 43
2014
Q2 		$44K Hold
100
– – 0.03% 41
2014
Q1 		$46K Hold
100
– – 0.03% 45
2013
Q4 		$48K Buy
+100
New +$48.9K 0.03% 47

Other funds holding IDXG

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
LCM
Leonard Capital Management Vero Beach, Florida $5.25M AUM
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Managed Asset Portfolios's IDXG Position: Q4 2014 in Review

Managed Asset Portfolios sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q4 2014, closing a stake of 100 shares — an estimated $24K sold.

Managed Asset Portfolios first reported a position in IDXG in Q4 2013 and held it in 4 quarters. The position peaked at $48K in Q4 2013. 26 funds tracked by Wall St. Rank hold IDXG as of Q4 2014.

  • Managed Asset Portfolios reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • Managed Asset Portfolios sold 100 Interpace Biosciences, Inc. Common Stock shares in Q4 2014, an estimated $24K.
  • Managed Asset Portfolios first reported a position in Interpace Biosciences, Inc. Common Stock in Q4 2013 and held it in 4 quarters.
  • Managed Asset Portfolios's Interpace Biosciences, Inc. Common Stock position peaked at $48K in Q4 2013.
  • 26 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q4 2014.

Based on Managed Asset Portfolios's 13F filing for Q4 2014, filed 17 Feb 2015.